ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Physician Assistant, Medical

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,943Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 76

$502K Total Retail Price of All Prescriptions

Rank: 2 out of 76

454 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 454 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

14% of this provider’s 454 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

2% of this provider’s 7,986 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
WARFARIN SODIUM 518 471 1 6
LEVOTHYROXINE SODIUM 430 352 2 1
OMEPRAZOLE 419 299 3 2
LISINOPRIL 346 289 4 5
SIMVASTATIN 313 266 5 3
METOPROLOL TARTRATE 266 223 6 11
POTASSIUM CHLORIDE 264 208 7 13
HYDROCODONE-ACETAMINOPHEN 235 163 S3 8 7
AMLODIPINE BESYLATE 215 195 9 4
FUROSEMIDE 205 169 10 8
GABAPENTIN 178 124 11 16
METFORMIN HCL 154 123 12 9
TRAMADOL HCL 147 99 13 14
BUMETANIDE 144 129 14 43
METOPROLOL SUCCINATE 137 118 15 10
SERTRALINE HCL 118 103 16 22
ROPINIROLE HCL 111 96 17 44
GLIMEPIRIDE 105 72 18 35
ALLOPURINOL 104 57 19 30
HYDROCHLOROTHIAZIDE 103 85 20 12
SYNTHROID 101 100 21 26
ALENDRONATE SODIUM 98 95 22 20
LISINOPRIL-HYDROCHLOROTHIAZIDE 96 76 23 29
CITALOPRAM HBR 90 80 24 19
CARVEDILOL 87 75 25 24
RAMIPRIL 84 78 26 71
LANTUS 84 75 26 32
ZOLPIDEM TARTRATE 84 51 26 23
AMITRIPTYLINE HCL 83 59 R 29 56
FENTANYL 81 57 S2 30 40
CALCITRIOL 79 47 31 73
ATORVASTATIN CALCIUM 78 56 32 17
LOSARTAN POTASSIUM 76 63 33 18
DILTIAZEM ER 74 62 34 75
CRESTOR 73 31 35 28
PANTOPRAZOLE SODIUM 72 72 36 41
DIOVAN 70 70 37 42
ATENOLOL 69 57 38 15
SPIRONOLACTONE 69 62 38 51
ADVAIR DISKUS 65 53 40 39
DIGOXIN 61 61 41 63
PREDNISONE 60 55 42 27
DONEPEZIL HCL 60 60 42 60
SINGULAIR 57 49 44 90
NAMENDA 55 45 45 50
FAMOTIDINE 53 41 46 95
PRAVASTATIN SODIUM 53 53 46 21
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 12, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.